Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 13, 2022 (4 years ago)

Diphenhydramine HCl oral solution (Diphenhydramine Hydrochloride)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations: Temperature abuse

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Diphenhydramine HCl oral solution, USP, 25 mg/10 mL UD, packaged in a) 10 mL unit dose cups (NDC 0121-0978-10), b) 100-count box (NDC 0121-0978-00), Rx only, MFG: Pharmaceutical Associates Inc.

Affected NDCs 0121-0978-00 0121-0978-10

Compare with the code on your package — it is the most precise check available.

Drug: Diphenhydramine Category: Allergy & Cold Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Diphenhydramine Hydrochloride
NDC 00121-0978
25 mg/10mL Solution
Oral
PAI Holdings, LLC dba PAI Pharma Rx
Recalling firm
Mckesson Medical-Surgical Inc. Corporate Office
NDC code
0121-0978-10
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1101-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Diphenhydramine recalls

See all
Class II · Moderate risk

Unisom

CGMP Deviations; detection of Nitrosamine Drug Substance-Related Impurities (NDSRI), N-nitroso-desmethyl-diphenhydramine (n-dph), above the FDA Recommended Intake Limit

Ongoing Nitrosamine impurity Chattem Inc D-0362-2025
Class II · Moderate risk

Unisom

CGMP Deviations: Nitrosamine Drug Substance Related Issue impurity above the daily acceptable intake limit defined by the Food and Drug Administration.

Ongoing Nitrosamine impurity Chattem Inc D-0266-2025
Class III · Low risk

Diphenhydramine HCl 50 mg

Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID.

Ongoing Labeling / mix-up Akron Pharma, Inc. NDC 71399-8026-02 D-0199-2025
Class III · Low risk

Diphenhydramine HCl 25 mg

Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID.

Ongoing Labeling / mix-up Akron Pharma, Inc. NDC 71399-8028-2 D-0198-2025
Class III · Low risk

Diphenhydramine HCl 25 mg

Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID.

Ongoing Labeling / mix-up Akron Pharma, Inc. NDC 71399-8028-1 D-0197-2025

Other recalls by Mckesson Medical-Surgical Inc. Corporate Office

All 2022 recalls
Class II · Moderate risk

Infuvite Adult

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 54643-5649-1 D-0401-2025
Class II · Moderate risk

Medroxyprogesterone Acetate Injectable Suspension

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55150-0330-01 D-0400-2025
Class II · Moderate risk

BENLYSTA (belimumab)

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 49401-102-01 D-0540-2025
Class II · Moderate risk

Evenity

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55513-880-02 D-0539-2025